PTI News and Press, Yumanity Therapeutics Inc Com From 06/01/20

Proteostasis Therapeutics (NASDAQ: PTI ) is up  21%  premarket after announcing results from in vitro studies evaluating the use of PTI-129 as a treatment for COVID-19. More news on: Proteostasis Therapeutics, Inc., Healthcare stocks news, Read more ...

BOSTON , June 1, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced results from in vitro studies evaluating t...

Proteostasis Therapeutics (PTI) is developing a combination therapy for cystic fibrosis that is ready to enter Phase 3 trials. The cystic fibrosis space has gotten a lot more competitive over the last few years as Vertex Pharmaceuticals (VRTX) has released several combination therapies that ne...

Proteostasis Therapeutics (NASDAQ: PTI ): Q1 GAAP EPS of -$0.19 beats by $0.07 . More news on: Proteostasis Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

BOSTON , May 15, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced financial results for the first quarte...

BOSTON , May 13, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced that Proteostasis management will prese...

BOSTON , April 13, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced it has received Scientific Advice from ...

Waitr Holdings (NASDAQ: WTRH ) +70%  as few consumer stocks are performing well during the rough road ahead. More news on: Waitr Holdings Inc., iFresh Inc., Biomerica, Inc., Stocks on the move, , Read more ...

Proteostasis Therapeutics (NASDAQ: PTI ): Q4 GAAP EPS of -$0.23 beats by $0.06 . More news on: Proteostasis Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

BOSTON , March 10, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) through theratyping, today announced financial result...